# MyOme

> MyOme is a clinical genomics company that sequences a patient’s genome and turns it into provider-ordered reports for preventive risk, medication response, and rare disease diagnosis. Its platform combines genetic findings with clinical factors and can reanalyze the same genome as knowledge and patient needs change.

- **Founded:** 2017
- **Headquarters:** Menlo Park, United States
- **Founders:** Matthew Rabinowitz (Co-founder and executive chairman), Akash Kumar (Co-founder and chief medical and scientific officer), Kate Im (Co-founder and senior vice president of research)
- **Products:** MyOme Atlas, MyOme Zenith, CAD iPRS, Type 2 Diabetes iPRS, Prostate Cancer iPRS
- **Notable:** Raised $23 million in a 2022 Series B, bringing disclosed funding then to more than $36 million., Operates a CLIA-certified, CAP-accredited clinical laboratory., Launched CAD, type 2 diabetes, and prostate cancer integrated risk reports in 2025.

## Products & services

- **MyOme Atlas** — Provider-ordered proactive screening platform with Curated Screen, Medication Response, and integrated risk reports for cardiometabolic disease and cancer.
- **MyOme Zenith** — Rare disease exome, genome, and copy-number diagnostics; commercial distribution through Natera.
- **CAD iPRS** — Integrated coronary artery disease risk report combining polygenic and clinical risk factors.
- **Type 2 Diabetes iPRS** — Integrated risk report for type 2 diabetes.
- **Prostate Cancer iPRS** — Integrated risk report for prostate cancer.
- **Long-read methylation analysis** — Analysis added for eligible rare disease cases to help interpret selected variants and imprinting conditions.

## Achievements

- Raised $23 million in a 2022 Series B, bringing disclosed funding then to more than $36 million.
- Operates a CLIA-certified, CAP-accredited clinical laboratory.
- Launched CAD, type 2 diabetes, and prostate cancer integrated risk reports in 2025.
- Expanded rare disease testing to include methylation analysis for eligible cases in 2026.
- Published 2026 coronary artery disease risk-model research in the American Journal of Preventive Cardiology.

## Latest updates

- **2026-03** — Announced Zenith distribution with Natera and long-read methylation analysis for eligible rare disease orders.
- **2026-03** — Announced published research on stability of integrated coronary artery disease risk prediction.
- **2025-12** — Announced Illumina collaboration and investment to support a planned prospective preventive-health trial.
- **2025-11** — Launched a prostate cancer integrated polygenic risk report.

## Links

- Website: https://myome.com/
- LinkedIn: https://www.linkedin.com/company/myome/
- Twitter/X: https://x.com/myomeinc
- GitHub: https://github.com/myome
- YouTube: https://www.youtube.com/watch?v=Si4RuyACO3M
- Bluesky: https://bsky.app/profile/myome.com

---

Profile page: https://yespress.io/myome
Published by YesPress — https://yespress.io
Last updated: 2026-09-28